Foghorn Therapeutics Inc.

Cytokinetics, Inc. CEO Robert Blum has maintained since the company reported positive topline Phase III results for the cardiac myosin inhibitor aficamten in obstructive hypertrophic cardiomyopathy (

Foghorn Therapeutics Inc. ’s lead drug candidate FHD-286 has the potential to treat both hematological malignancies and solid tumors, but its future in acute myeloid leukemia (AML) and myelodysplastic

Foghorn Therapeutics Inc. ’s development program for FHD-286 has run into trouble as the US Food and Drug Administration has placed a partial clinical hold in acute myeloid leukemia (AML) and myelodys

Targeted protein degradation, or TPD, has been steadily gaining attention in recent years as a highly promising new drug development strategy that has already attracted significant investment and big